CTOs on the Move

Akriveia Therapeutics

www.akrevia.com

 
`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.akrevia.com
  • LabCentral 610 610 Main Street
    Cambridge, MA USA 02139
  • Phone: 602.226.2389

Executives

Name Title Contact Details

Funding

Akriveia Therapeutics raised $30M on 09/27/2018

Similar Companies

CellzDirect Inc

CellzDirect Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miltenyi Biotec

We`re committed to helping researchers and clinicians make a greater impact on science and health. For more than 25 years, our work has played an essential role in the cell research and cell therapy community. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our integrated technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. This complete portfolio enables the access, analysis, and utilization of primary and primary-derived cells. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries.

AandL Catheter Technologies

A&L Catheter Technologies is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Western Oncolytics

Western Oncolytics is developing a new generation of oncolytic viral immunotherapies to help patients accross the globe beat cancer

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.